J Korean Med Assoc.  2021 Jun;64(6):449-454. 10.5124/jkma.2021.64.6.449.

Pharmacotherapy for female nocturia

• Kim SR

• KMID: 2516797
• DOI: http://doi.org/10.5124/jkma.2021.64.6.449

Abstract

Background
In 2018, nocturia and nocturnal lower urinary tract function definitions were updated in a clinically and practically based consensus report by the International Continence Society Standardization Steering Committee. Previous research has suggested that the pathophysiology of nocturia has a multifactorial etiology, including obstructive sleep apnea, overactive bladder syndrome, diabetes mellitus, sleep disturbance, congestive heart failure, primary polydipsia, and other factors.
Current Concepts
Three main mechanisms have been identified: low functional bladder capacity, nocturnal polyuria, and diurnal polyuria (24-hour polyuria). Multifactorial pathophysiology implies multiple possible targets for therapeutic intervention, and suggests that it is unlikely that one treatment modality, including drugs, will be successful in all patients. The bladder diary is the most important diagnostic tool.
Discussion and Conclusion
Strong evidence supports the efficacy of desmopressin and continuous positive pressure breathing. Antimuscarinic drugs for treating nocturia display limited usefulness because of their low efficacy for nocturnal polyuria. Management of nocturia may require a multidisciplinary approach to visualization and phenotyping of patients for diagnosis and therapy.

Keyword

Nocturia; Female; Pharmacotherapy; Desmopressin; 야뇨증; 여성; 약물치료; 데스모프레신